Abstract
Pancreatic cancer is an aggressive cancer disease and bears a dismal prognosis. Data on gender differences in this tumor entity are scare. In this single center, real-world retrospective analysis of our registry for pancreatic cancer, we investigated and compared the survival data and inflammatory parameters of male and female patients. In total, we included in this analysis 42 female and 63 male patients with metastatic pancreatic cancer. Liver metastasis was comparable between the genders (69.0% for female and 68.3% for male patients). Female patients were older at time of initial diagnosis (70.5 versus 69.7 years). Median overall survival (OS) rates from initial diagnosis were 13.4 months (95% CI: 7.6-19.1) and 7.0 months (95% CI: 3.2-10.9; p = 0.013), respectively. CRP/albumin ratio was significantly lower in female patients (p = 0.039). CRP/albumin ratio (HR = 7.7, p = 0.012) and CEA (HR = 1.0, p = 0.821) were independent prognostic factors for OS. Based on our retrospective analysis, female patients had a significantly longer OS than male patients with metastatic pancreatic cancer, maybe due to a lower inflammatory activity as reflected by the CRP/albumin ratio.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
